We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+18.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.6B
AUM Growth
+$886M
Cap. Flow
+$142M
Cap. Flow %
2.54%
Top 10 Hldgs %
40.08%
Holding
154
New
29
Increased
38
Reduced
31
Closed
27

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.3M
2
BMY icon
Bristol-Myers Squibb
BMY
+$82.6M
3
SHPG
Shire pic
SHPG
+$76.4M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$50.3M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$49.2M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$149M
2
INCY icon
Incyte
INCY
+$33.4M
3
MAKO
MAKO SURGICAL CORP COM
MAKO
+$26.7M
4
PFE icon
Pfizer
PFE
+$25.6M
5
AGN
Allergan plc
AGN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.56%
2 Financials 1.77%
3 Technology 0.15%
4 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMBI
51
DELISTED
Ambit Biosciences Corp
AMBI
$23.1M 0.41%
1,490,769
– –
MDT icon
52
Medtronic
MDT
$113B
$21.8M 0.39%
410,000
+217,700
+113% +$11.7M
AGN
53
CALL
DELISTED
Allergan plc
AGN
$21.6M 0.39%
150,000
+9,300
+7% +$1.24M
TECH icon
54
Bio-Techne
TECH
$11.2B
$21.3M 0.38%
1,064,000
+720,000
+209% +$13.7M
IQV icon
55
IQVIA
IQV
$40.5B
$19.7M 0.35%
440,000
– –
WCG
56
DELISTED
Wellcare Health Plans, Inc.
WCG
$19M 0.34%
272,000
+39,000
+17% +$2.5M
ATRS
57
DELISTED
Antares Pharma, Inc.
ATRS
$17.7M 0.32%
4,365,000
-4,834,000
-53% -$21.1M
MRTX
58
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$17.4M 0.31%
+1,149,332
New +$11.3M
CERS icon
59
Cerus
CERS
$577M
$17.2M 0.31%
+2,557,900
New +$13.9M
RCPT
60
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$16.7M 0.3%
644,450
– –
DRTX
61
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$16.1M 0.29%
1,785,714
– –
A icon
62
CALL
Agilent Technologies
A
$39.6B
$15.4M 0.27%
419,400
+26,143
+7% +$881K
BHC icon
63
Bausch Health
BHC
$1.7B
$14.4M 0.26%
138,000
– –
ONXX
64
PUT
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$14M 0.25%
+112,300
New +$14.2M
ABT icon
65
Abbott
ABT
$191B
$13.3M 0.24%
400,000
-80,000
-17% -$2.81M
XOMA
66
DELISTED
Xoma
XOMA
$12.5M 0.22%
139,354
+10,058
+8% +$914K
ALXN
67
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$11.6M 0.21%
+100,000
New +$11M
BMY icon
68
CALL
Bristol-Myers Squibb
BMY
$130B
$11.6M 0.21%
250,000
-50,000
-17% -$2.19M
TEVA icon
69
PUT
Teva Pharmaceuticals
TEVA
$39.8B
$11.3M 0.2%
+300,000
New +$11.7M
CYH icon
70
Community Health Systems
CYH
$388M
$11.3M 0.2%
329,120
+36,300
+12% +$1.29M
SVA
71
DELISTED
Sinovac Biotech, Ltd
SVA
$11.3M 0.2%
1,884,200
– –
MRGE
72
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$11.2M 0.2%
+4,296,000
New +$14.4M
ABBV icon
73
CALL
AbbVie
ABBV
$472B
$11.2M 0.2%
+250,000
New +$11.1M
BAX icon
74
Baxter International
BAX
$12.7B
$10.7M 0.19%
299,715
– –
DVAX
75
DELISTED
Dynavax Technologies
DVAX
$10.7M 0.19%
898,600
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2013 Portfolio in Review

As of Q3 2013, OrbiMed held 154 positions worth $5.6B, up 19% from $4.72B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2013 filing shows 29 new, 38 increased, 31 reduced and 27 closed positions. Its largest new stake was Shire pic: 690,900 shares worth $82.8M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2013 buy was Shire pic: 690,900 shares worth $82.8M.
  • OrbiMed added most to Merck in Q3 2013, an estimated $93.3M increase.
  • OrbiMed's biggest Q3 2013 reduction was Incyte, cutting an estimated $33.4M.
  • OrbiMed fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 40% of its $5.6B portfolio in Q3 2013.
  • OrbiMed opened 29 new positions and closed 27 in Q3 2013.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $5.6B.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.